These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35834523)

  • 1. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB.
    Pagano MB; Foroutan F; Goel R; Allen ES; Cushing MM; Garcia DA; Hopkins CK; Klein K; Raval JS; Cohn CS
    Transfusion; 2022 Aug; 62(8):1652-1661. PubMed ID: 35834523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.
    Holland L; Warkentin TE; Refaai M; Crowther MA; Johnston MA; Sarode R
    Transfusion; 2009 Jun; 49(6):1171-7. PubMed ID: 19210325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergent reversal of vitamin K antagonists: addressing all the factors.
    Martin DT; Barton CA; Dodgion C; Schreiber M
    Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
    Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
    Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
    Pabinger I; Brenner B; Kalina U; Knaub S; Nagy A; Ostermann H;
    J Thromb Haemost; 2008 Apr; 6(4):622-31. PubMed ID: 18208533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs.
    DeAngelo J; Jarrell D; Cosgrove R; Camamo J; Edwards C; Patanwala AE
    Am J Ther; 2018; 25(3):e326-e332. PubMed ID: 28763307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
    Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
    Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department.
    Hickey M; Gatien M; Taljaard M; Aujnarain A; Giulivi A; Perry JJ
    Circulation; 2013 Jul; 128(4):360-4. PubMed ID: 23770745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation.
    Riess HB; Meier-Hellmann A; Motsch J; Elias M; Kursten FW; Dempfle CE
    Thromb Res; 2007; 121(1):9-16. PubMed ID: 17407788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding.
    Schick KS; Fertmann JM; Jauch KW; Hoffmann JN
    Crit Care; 2009; 13(6):R191. PubMed ID: 19948037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.
    Puchstein D; Kork F; Schöchl H; Rayatdoost F; Grottke O
    Thromb Haemost; 2023 Jan; 123(1):40-53. PubMed ID: 36626899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis.
    Condeni MS; Weant KA; Neyens RR; Eriksson EA; Miano TA
    Am J Emerg Med; 2024 Mar; 77():91-105. PubMed ID: 38118388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate.
    Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC
    World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
    Brekelmans MPA; Ginkel KV; Daams JG; Hutten BA; Middeldorp S; Coppens M
    J Thromb Thrombolysis; 2017 Jul; 44(1):118-129. PubMed ID: 28540468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.